MedTrace Logo

Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19

NCT04403880 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 760

Last updated 2026-01-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to learn more about infection with and recovery from the virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Some people know this virus by the name "coronavirus." It can cause the disease called COVID-19.

The information gained from the study will be used to help develop better tests for SARS-CoV-2 infection and COVID-19 disease and may help in developing future vaccines and treatments by allowing researchers to determine the difference between the body's immune response to natural SARS-CoV-2 infection and immunization with a SARS-CoV-2 vaccine.

Conditions

Interventions

OTHER

Sample collection

* Optional nasal specimen(s) * Blood collection

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • HIV Prevention Trials Network

    collaborator NETWORK

  • HIV Vaccine Trials Network

    lead NETWORK

Principal Investigators

  • Larry Corey · HIV Vaccine Trials Network, Fred Hutch

  • Shelly Karuna · HIV Vaccine Trials Network, Fred Hutch

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-13
Primary Completion
2022-04-21
Completion
2022-04-21

Countries

  • United States
  • Malawi
  • Peru
  • South Africa
  • Zambia
  • Zimbabwe

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04403880 on ClinicalTrials.gov